Evidence map›Paper›PMID 38487949›Full record

ArticleCancer science2024

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer.

Zhuo Cheng, Cheng Yang, Qian Zhao, Jingjiao Zhong, Jin Zhang, Riming Jin, Yao Li, Na Ta, Dong Wu, Zhengang Yuan and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhuo ChengDepartment of Oncology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Cheng YangDepartment of Special Treatment I and Liver Transplantation, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Qian ZhaoDepartment of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jingjiao ZhongDepartment of Radiology, Changhai Hospital, Naval Medical University, Shanghai, China.
Jin ZhangThe First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Riming JinThe First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yao LiThe First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Na TaDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai, China.
Dong WuThe First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Zhengang YuanDepartment of Oncology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Wen SunNational Center for Liver Cancer, Naval Medical University, Shanghai, China.
Ruoyu WangThe First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-0946-6881
Second Military Medical University · CNNaval University of Engineering · CNShanghai Jiao Tong University · CN

Funding

National Natural Science Foundation of China 81972777National Natural Science Foundation of China 81972810National Natural Science Foundation of China 82003161National Natural Science Foundation of China 82373300Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 20YF1459600Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 21Y11912600Shanghai Municipal Health Commission 202140364Shanghai Municipal Hospital Development Center SHDC2020CR4040
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have shown promising efficacy in multiple cancers including biliary tract cancers (BTCs). However, the data focusing on the efficacy of ICIs in patients with gallbladder cancer (GBC) is still limited. In this study, we aim to assess the efficacy of ICIs in GBC and explore the clinicopathologic and molecular markers associated with ICI benefit. We retrospective analyzed 69 GBC patients who had received ICI therapy between January 2016 and December 2020. Tumor samples were obtained for genomic sequencing and immunohistochemical analysis. The median progression-free survival (PFS) and overall survival (OS) was 4.4 months and 8.5 months, respectively. Multivariate analysis indicated that alcohol intake history, carcinoma embryonic antigen (CEA) level ≥100 U/mL, and cutaneous immune-related adverse events (irAEs) were independent prognostic factors for PFS. CEA level ≥100 U/mL and cutaneous irAEs were independent prognostic factors for OS. The objective response rate and disease control rate (DCR) were 15.9% and 37.7%, respectively. Patients with cutaneous irAEs, high CD8

Indexed as

Gallbladder NeoplasmsImmune Checkpoint InhibitorsAdultAgedAged, 80 and overBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeBiomarkers, TumorImmune Checkpoint Inhibitorsgallbladder cancerimmune checkpoint inhibitorsPD‐1PD‐L1

Identifiers

PMID38487949
PMCPMC11145113
OpenAlexW4392852062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.